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Abstract 
Clinical Pharmacology and Therapeutics (CPT), the definitive and timely source for advances in 
human therapeutics, transcends the drug discovery, development, regulation and utilization 
continuum to catalyze, evolve and disseminate discipline-transformative knowledge. Prioritized 
themes and multidisciplinary content drive the science and practice of clinical pharmacology, 
offering a trusted point of reference. An authoritative herald across global communities, CPT is 
a timeless information vehicle at the vanguard of discovery, translation and application 
ushering therapeutic innovation into modern health care. 
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A decade into joining the editorial team of Clinical Pharmacology and Therapeutics (CPT), we 
here reflect on the Journal’s ongoing evolution. CPT is foremost an enduring asset of the 
American Society of Clinical Pharmacology and Therapeutics, and more broadly an authoritative 
source of knowledge in the dynamic discipline of clinical pharmacology and human 
therapeutics.1 Recognized as a premier vehicle for disseminating new concepts, ideas, and 
information, CPT serves as a principle and trusted portal to the discipline.2 It has steadily 
anchored a multi-disciplinary field central to translational and applied clinical medicine, 
advancing human health by focusing on the nature, activity, efficacy and regulatory analysis of 
therapeutics.3 Building on a platform of key values at the core of clinical pharmacology and 
therapeutics, CPT has matured into a global forum at the center of diversified communities of 
practice driving discovery, development, regulation and utilization of therapeutics, the DDRU 
continuum, in this evolving time of systems biology and precision therapeutics.2 Indeed, as in 
past years, each of our thematic issues in 2016 underscores key advances, or emerging 
domains, within the field including therapeutic innovations,4 precision medicine,5 big data,6 
therapeutic optimization,7 epigenetics,8, 9 the microbiome,10 pregnancy and lactation,11 
thrombosis,12 immune-oncology,13 rare diseases,14 transporters,15 and adaptive biomedical 
innovation16. 
CPT has in fact expanded its utility, appeal, and relevance, underscored by a 25% 
increase in manuscript downloads in 2016 compared to the previous year. As utilization has 
increased, the Journal continues to support a rigorous peer review program, orchestrated by 
Associate Editors with deep domain expertise covering the landscape of clinical pharmacology 
and its many facets.1 In that context, peer review seeks to identify manuscripts that describe 
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new therapeutic paradigms, reveal novel mechanistic insights, define evolving regulatory 
strategies, or in other ways transform or expand the dimensions of practice in clinical 
pharmacology. The impact of the content of CPT can be appreciated by considering the breadth 
of its audience, with more than 2,000,000 online page views in the last two years. The high 
quality of papers published and their ability to influence the discipline is highlighted by the 
continued outstanding performance of the impact factor, which was at 7.268 in 2015. The 
consistency of impact maintains CPT as a top journal publishing original research articles in the 
category of pharmacology and pharmacy of the Institute for Scientific Information (ISI). 
Beyond original research, CPT serves as an essential vehicle to expand the 
dimensionality of the discipline of clinical pharmacology for clinicians, drug developers, 
laboratory scientists and regulators, across multinational communities of practice. The Journal 
highlights emerging scientific fields, developing therapeutic innovations, advances in the 
science of drug development, and evolving regulatory strategies that complement the 
application of new platform technologies, to keep our readership informed and current about 
the broad evolution of this highly vibrant discipline.17-19 Moreover, the Journal showcases 
current controversies in the field, highlights notable achievements by our members, and serves 
as a scholarly forum for discussion and debate that underscores the relevance of our discipline 
to societal issues around the globe.19 This has been accomplished, in part, by experimenting 
with innovative thematic content over the last 10 years which, in many ways, has evolved into a 
unique identity for the Journal. Established components which have garnered popularity with 
the readership include Commentaries20 and Point-Counterpoint, which offer context for 
practice-changing science in original research papers or thoughtfully highlight ongoing 
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controversies and debates in our discipline. Macroscopy21 continues to remind us that our 
discipline impacts, and is impacted by, the larger canvas of geopolitical, socioeconomic, and 
environmental issues that bind us in a global community. The latest innovations in molecular, 
clinical, and regulatory sciences are showcased in Opinion pieces, including Discovery,22 
Translation,23 and Development24, 25. Moreover, State of the Art26 and Reviews27 offer 
authoritative synthetized content, reflected by their high rate of citations, providing in-depth 
analysis of emerging trends in the practice of clinical pharmacology. 
Beyond those established components, during the last 5 years we added new content to 
CPT, to continue the evolution of the journal and keep the readership ahead of advancing 
trends in the discipline. Innovation in precision medicine, with a particular focus on therapeutic 
selection reflecting the molecular fingerprints of pathobiology, is revolutionizing patient 
management. In turn, these advances have been driven by the dual engines of discovery and 
development, fed by the deconvolution of elemental biology coupled with technology 
platforms that are transforming medicine. To capture these developments for the readership, 
which span the continuum from discovery to application, we instituted an annual January issue 
dedicated to Therapeutic Innovations that are changing the practice of healthcare.28, 29 Further, 
in recognition of the essential role that drug development plays in the evolution of biological 
discoveries into human therapies, we have developed a strategic focus on Clinical Trials,30, 31 
the essential bridge between scientific and technical innovation and clinical translation and 
application. Moreover, it is clear that genetics and genomics have transformed our 
understanding of drug action, permitting the optimization of therapeutics for individuals and 
populations. One challenge in productively linking science and medicine generally, and in 
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translating genomic discoveries in the laboratory to better therapies in patients specifically, is 
advancing experimental insights into clinical practice. In that regard, we have been privileged to 
collaborate with the Pharmacogenomics Research Network (PGRN), the Pharmacogenomics 
Knowledge Base (PharmGKB), and the Clinical Pharmacogenetics Implementation Consortium 
(CPIC)32-34 to disseminate practice guidelines that define how practitioners can use genetic and 
genomic information to best tailor therapies to individual patients. 
As a discipline leader, Clinical Pharmacology and Therapeutics translates relevant 
progress in science and technology into innovations that maintain wellness and health and 
transform the management of disease. In an effort to keep readership on the advancing edge of 
the technological wave and maintain its relevance to careers in the discipline, we will embark 
on several new initiatives during the next stage of the Journal’s evolution. We have heard the 
voices of the readership which have underscored the importance of a greater focus on 
showcasing original research from our membership across diverse communities of practice. 
Thus, we are working with our Wiley publishing colleagues and ASCPT to create the ability and 
greater opportunities to publish a larger number of original research articles that span the 
DDRU continuum in each issue. In that context, we invite members of the Society, specifically, 
and the discipline overall to submit original research for consideration by the Journal. Also, the 
popularity of CPICs, reflecting the importance of expertly curated information to translate 
innovation into practice, is driving our efforts to explore the possibility of collaborations with 
other organizations to produce practice guidelines advancing diagnosis and treatment. Further, 
we recognize the increasing contribution of investigators at the earliest stages of molecular 
discoveries to the discipline of clinical pharmacology and the development of innovations in 
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diagnosis and treatment. Thus, we will expand the overall focus of the journal to include 
original research at the earliest stages of the DDRU continuum. Moreover, the ASCPT 
publication portfolio has expanded with the addition of Clinical and Translational Science 
(CTS), and we are looking forward to increasing our interactions, along with CPT:PSP, to 
maximize the synergies that these inter-related journals offer. With these combined efforts, 
CPT looks forward to expanding and enhancing the relevance of our content, disseminating 
transformative science, and catalyzing discussions about issues confronting the discipline that 
are essential to our highly diverse communities of practice. 
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